How Long Until Lu-177 PSMA Shrinks Your Tumor — What Response Timelines and Scans Show About Treatment Success

Why Patients Ask: When Will I Know If This Is Working?

When you start Lu-177 PSMA therapy, one of the first questions men ask is: when will I know if this is helping? The answer isn't simple. Your PSA may begin to fall within weeks of your first infusion. But the most important signs of response — stable or shrinking tumors on imaging — take longer to show up. Knowing what to look for and when can help you and your care team track your progress.

The Tools Doctors Use to Track Response

No single test tells the whole story about how Lu-177 PSMA therapy is working. Your oncology team will typically monitor several measures together:

• PSA blood test: Prostate-specific antigen rises when prostate cancer is active. A falling PSA often signals that treatment is having an effect.
• CT scan: Shows whether soft-tissue tumors have grown, shrunk, or stayed stable.
• Bone scan: Tracks whether bone metastases are spreading or holding steady.
• PSMA PET/CT scan: A specialized imaging tool that shows where PSMA protein — found in high amounts on prostate cancer cells — is active in the body. It is required before treatment to confirm eligibility and may be repeated during or after therapy to assess response.
• Symptoms and quality of life: How you feel day to day — pain levels, energy, daily function — is also a meaningful measure of whether treatment is helping.

PSA Response: What the Numbers Show

PSA is typically checked before each treatment cycle. In men with metastatic castration-resistant prostate cancer (mCRPC) receiving Lu-177 PSMA therapy, about 66% experience some PSA decline after the first cycle. About 40% have what researchers call a PSA50 response — a drop of 50% or more from their starting level, according to a peer-reviewed analysis of Lu-177 PSMA therapy in mCRPC published in PubMed Central.

After the second cycle, these rates improve. About 57% of patients reach a PSA50 response, and roughly 72% experience some PSA decline. By about 8 weeks after the first cycle, close to 79% of patients have a lower PSA level.

One important thing: PSA can temporarily rise in the first few weeks after an infusion before it starts to fall. This is called a PSA flare. Most clinical protocols recommend waiting at least 12 weeks before judging how you're responding based on early PSA changes. If your PSA rises slightly after your first infusion, ask your care team if this might be a temporary flare rather than disease getting worse.

What the VISION Trial Tells Us About Response

Most evidence on Lu-177 PSMA therapy comes from the VISION trial — the phase 3 clinical study that led to FDA approval of this treatment for men with mCRPC. Men in the trial had received at least one hormone therapy and at least one taxane chemotherapy before joining.

According to the National Cancer Institute summary of the VISION results, patients who received Lu-177 PSMA-617 plus standard care had:

• Median overall survival of 15.3 months, compared to 11.3 months for standard care alone
• Radiographic progression-free survival — the time before tumors grew on imaging — of 8.7 months, compared to 3.4 months for standard care
• A hazard ratio for death of 0.62, suggesting roughly 38% lower risk of death during the study period

As Memorial Sloan Kettering Cancer Center noted at the time of FDA approval, this was a real improvement for men with few treatment options left. But remember: these are average results from a clinical trial. Your own outcome will depend on your specific cancer, what treatments you've had before, and your overall health.

To see more clinical trial evidence, read our related article: What Do the Latest Clinical Trial Results Tell Us About Lu-177 PSMA Therapy for Stage 4 Prostate Cancer?

How Scans Track Response During and After Treatment

Three main types of imaging are used to monitor response during Lu-177 PSMA therapy.

PSMA PET/CT scan: Before treatment starts, this scan confirms that your tumors have enough PSMA protein to be targeted. During or after treatment, a repeat PSMA PET/CT shows whether cancer cells are taking up less of the tracer — usually meaning less active disease. Research on PSMA PET-based response assessment during Lu-177 radioligand therapy shows that measurable imaging changes can predict survival outcomes. These include how brightly lesions glow on the scan (called standardized uptake value, or SUV) and the total volume of PSMA-active tumor. Patients whose tumors showed less PSMA activity on follow-up scans tended to have better long-term results.

Post-therapy SPECT/CT scan: After each Lu-177 infusion, the lutetium-177 emits gamma rays that a whole-body scan can detect. This scan, done in the first few days after each infusion, shows where the treatment went and where tumors took it up. A study comparing early treatment response assessment methods found that these post-therapy scans can help check early response — a practical option between formal PSMA PET/CT appointments.

CT and bone scan: Standard CT scans and technetium bone scans are typically repeated every 2 to 3 cycles. CT tracks changes in soft-tissue lesions. Bone scans measure disease in the skeleton. If your CT shows stable disease — meaning tumors haven't grown, even if they haven't visibly shrunk — that's still a good outcome in advanced cancer.

If you want to understand how PSMA PET scan results affect treatment eligibility, our article on what mixed PSMA PET scan results mean for qualifying for Lu-177 PSMA therapy explains this.

When Response Is Usually Assessed

Lu-177 PSMA therapy is usually given as up to 6 cycles, spaced about 6 weeks apart. Most oncology teams assess response at these times:

• Before each cycle: PSA blood test and basic lab work, including kidney function and blood cell counts
• After cycles 2 to 3: First formal imaging assessment, usually CT scan and bone scan
• After cycles 4 to 6: Follow-up imaging, which may include a repeat PSMA PET/CT scan at some centers
• Within 1 to 3 days after each infusion: Post-therapy SPECT/CT scan, where available, to provide an early picture of drug uptake

In some cases, an interim PSMA PET scan after 2 to 3 cycles helps clarify whether a lesion is responding when standard CT or bone scan results aren't clear.

Symptom and Pain Relief — Sometimes Ahead of the Scans

One finding that surprises patients: you can feel better before scans show tumor shrinkage. Bone pain from metastases may ease within weeks of your first infusion in some men, as the Lu-177 radiation targets cancer cells in bone lesions.

The VISION trial showed that patients receiving Lu-177 PSMA-617 reported better pain outcomes and quality of life than those receiving standard care alone. If your scan results after two cycles aren't clear but you feel much better — less pain, more energy, fewer pain medications — tell your oncologist. Symptom improvement is real clinical information and matters as much as PSA numbers.

For more on bone pain relief with this treatment, see our article: My Bone Metastases Are Causing Severe Pain — Can Lu-177 PSMA Therapy Help?

What Factors Influence How Fast You Respond

Several things affect how quickly and how well Lu-177 PSMA therapy works for you:

• PSMA expression level: Higher PSMA expression on tumor cells usually means better treatment uptake and often a stronger response.
• Tumor volume and burden: Men with fewer metastases and lower tumor burden tend to show stronger responses.
• Prior treatment history: Cancers that have had many previous treatments may respond differently than those that haven't.
• Kidney and bone marrow function: These organs process radiation from Lu-177. How well they work affects how much treatment you can safely receive and complete.
• Tumor heterogeneity: When some lesions are PSMA-positive and others aren't, the PSMA-negative lesions don't get a therapeutic dose. Mixed disease can make response harder to assess.

What If PSA Doesn't Fall?

Different studies show response rates ranging from about 10% to 69%, which reflects how different patients and tumor types are. Not everyone has a big PSA drop. But that doesn't mean the treatment is failing.

Some men have stable disease — their PSA doesn't climb quickly and tumors don't visibly grow on scans. This is still meaningful progress in advanced cancer. But if PSA rises for two or more consecutive cycles and scans show tumor growth, your care team will talk about whether to continue, pause, or try other treatments. Doctors are using data from the VISION trial to build prediction models that help identify who's likely to benefit. These models use baseline PSA, PSMA PET tumor volume, and other pretreatment factors to give a clearer picture before treatment starts.

Questions to Ask Your Oncology Team

If you're starting or already getting Lu-177 PSMA therapy, these questions can help you talk about monitoring with your care team:

• What is my PSA trend from cycle to cycle, and how do you interpret it?
• When will my first imaging assessment happen?
• Will I receive a post-therapy SPECT scan after each infusion?
• Are any of my lesions appearing PSMA-negative on follow-up imaging?
• Based on my baseline data, what kind of response do you expect for me?
• At what point would you consider changing or stopping my treatment plan?

When to Talk to Your Doctor

Talk to your oncologist right away if you notice new or worsening pain — especially in the spine or pelvis — unexplained fatigue, bruising, or signs of low blood counts like shortness of breath. Also let them know if your PSA rises for two or more cycles in a row. These might or might not mean your disease is changing, but your doctor can help you understand what's happening in your situation.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.